Align Technology Beats Q1 Expectations with Record Clear Aligner Shipments

Align Technology (NASDAQ: ALGN) delivered stronger-than-expected first quarter 2026 results, with record Invisalign clear aligner shipments of 685,700 cases powering a 6.2% year-over-year revenue increase to $1.04 billion. The dental technology leader also announced a new $200 million stock repurchase program, signaling confidence in its growth trajectory.

Key Numbers

The orthodontic innovator reported non-GAAP diluted earnings per share of $2.58 for Q1 2026, representing a 21% increase from $2.13 in the year-ago quarter. On a GAAP basis, earnings came in at $1.57 per share, up from $1.27 in Q1 2025.

Revenue reached $1.04 billion, exceeding management's guidance and marking a 6.2% year-over-year increase despite a modest 0.7% sequential decline. The company benefited from favorable foreign exchange impacts of approximately $44.9 million compared to the prior year, contributing 4.5 percentage points to the growth rate.

Clear Aligner revenues, which represent 82% of total sales, climbed 7.4% year-over-year to $856.0 million. This growth was driven by a 6.7% increase in case volumes to a record 685,650 shipments, with particular strength in international markets. The EMEA, APAC, and LATAM regions all delivered double-digit growth, while North America showed stability.

Profitability metrics remained robust, with non-GAAP gross margin reaching 71.8% and non-GAAP operating margin at 21.5%. The company generated net income of $112.8 million on a GAAP basis, or $184.6 million on a non-GAAP basis.

What Management Said

CEO Joe Hogan expressed satisfaction with the quarter's performance, stating, "We're pleased to report another better-than-expected quarter, with Q1'26 revenues, Clear Aligner volumes, and both GAAP and non-GAAP operating margins exceeding our outlook."

Hogan highlighted the company's balanced growth across customer segments, noting that orthodontic shipments increased 7.4% year-over-year while general practitioner dentist shipments rose 5.6%. The CEO also emphasized momentum across all age demographics, with adult patients up 7.8% and teen/kid patients growing 4.8% year-over-year.

Management pointed to dental service organizations (DSOs) as a "force multiplier" continuing to drive double-digit Clear Aligner volumes globally. The company also noted continued adoption of its iTero Lumina full systems and growth in services revenues, though the Imaging Systems segment experienced expected seasonal softness, declining 12.1% sequentially to $184.1 million.

Looking ahead, management reaffirmed full-year 2026 guidance, expecting worldwide revenue growth of 3% to 4% and mid-single-digit Clear Aligner volume growth. For Q2 2026, the company projects revenues between $1.04 billion and $1.06 billion, representing 3% to 5% year-over-year growth.

Importantly, management acknowledged ongoing uncertainty related to Middle East conflicts, noting they've taken a "prudent approach" in Q2 guidance by assuming some impact on both clear aligner and scanner demand. However, Q1 impact from the region was deemed "immaterial."

What to Watch

Several key developments merit investor attention going forward. First, the company's international expansion continues to outpace North American growth, with double-digit increases across EMEA, APAC, and LATAM regions suggesting successful market penetration strategies. This geographic diversification could provide resilience against regional economic headwinds.

The new $200 million stock repurchase authorization, set to begin May 1, 2026, demonstrates management's confidence in cash generation and long-term prospects. With $800 million remaining under the broader $1 billion program and approximately $1.06 billion in cash and equivalents, Align maintains significant financial flexibility.

Margin expansion remains a priority, with management targeting approximately 400 basis points of GAAP operating margin improvement for fiscal 2026 compared to 2025. The company expects to reach nearly 18% GAAP operating margin and 23.7% non-GAAP operating margin for the full year.

Investors should monitor the evolving tariff landscape following recent regulatory changes. While management doesn't expect material impact from the transition from IEEPA tariffs to Section 122 tariffs, any future trade policy shifts could affect the company's cost structure.

The company's strategic focus areas for 2026 include advancing its Align Digital Platform, scaling the iTero Lumina ecosystem, and building a differentiated portfolio for younger patients. With capital expenditure guidance of $125-150 million focused on technology upgrades and manufacturing capacity, Align appears positioned to support continued growth.

Geopolitical risks, particularly Middle East tensions affecting patient traffic and consumer sentiment, remain a wildcard. While Q1 impact was minimal, management's cautious Q2 outlook suggests vigilance is warranted as the situation evolves.

---

*StockCliff Research*